← All tickers

Is CLYM Worth Buying in 2026?

Climb Bio, Inc. Common Stock

STOCK PHARMACEUTICAL PREPARATIONS Updated 2026-08-16

Here’s whether Climb Bio, Inc. Common Stock (CLYM) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.

🟢
Bullish

Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+4.31% over 10 days); strong 1-year return of +849.4%; 3-month momentum positive (+51.2%). Concerns: RSI 77 — overbought, elevated pullback risk. Currently 3.9% off its 52-week high. Score: +5/7.

Ready to act on this? 📈 Trade on Webull

CLYM is in a confirmed uptrend, trading above both its 50-day ($12.66) and 200-day ($7.65) moving averages. With an RSI of 76.8, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +849.4% compares to +20.4% for SPY (beat the market by 829.0%).

$10,000 invested 1 year ago → $94,942 today
vs. S&P 500 (SPY) — same period beat market by 829.0%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

✓Above 200-day MA ($7.65)
✓Above 50-day MA ($12.66)
!RSI(14) neutral zone (30–70) — currently 76.8
✓Positive return (+849.4%)
✓Within 10% of period high (−3.9%)
Period Range $16.33
$1.54 $17.00
RSI (14) 76.8
0 · OversoldOverbought · 100

Key Metrics

Price$16.33
Period Return+849.4%
Period High$17.00
Period Low$1.54
Drawdown−3.9%
MA-50$12.66
MA-200$7.65
RSI (14)76.8
Avg Volume (30d)1.2M
vs. SPYbeat by 829.0%
Return Rank#14 of 1252

Trade CLYM

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers